1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107 .
2. Casanovas O. Cancer: limitations of therapies exposed. Nature. 2012;484(7392):44–6. doi: 10.1038/484044a .
3. Tanner NT, Sherman CA, Silvestri GA. Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. Transl Lung Cancer Res. 2012;1(2):96–8. doi: 10.3978/j.issn.2218-6751.2012.03.02 .
4. Hwang JA, Song JS, Yu DY, Kim HR, Park HJ, Park YS, et al. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(6):6627–35.
5. Dotsch MM, Kloten V, Schlensog M, Heide T, Braunschweig T, Veeck J, et al. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients’ outcome. Epigenetics. 2015. doi: 10.1080/15592294.2015.1078049 .